• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

April Layoffs?

Quote
anonymous said:
I just want to say portfolio selling is a terrible idea. We are selling about 14 products right now in Diabetes....with all of the combos. The doctors are confused as hell as it is, which is why we have no FDC sales. Adding other products to the bag will dilute an already strongly performing sales force. The only reason we didn't hit our number was the goals were outrageous to begin with and started missing in diabetes when the competition started giving their drug away for free. Cant complete with free. Too late to that party in November. Any knee jerk reaction will push us further down. I do see getting rid of CV and letting Pradaxa go by the wayside when it goes off patent, but give the Cards to diabetes and sales will skyrocket! 100% coverage will more than make up for this year, but hey, if you can't send 25B home...
Click to expand...

You're funny. The CV team is BY FAR the most clinically savvy selling group in B.I. They have been battling the competition for years now with probably 1/4 the resources and headcount that Eliquis and Xarelto have had, all within an arena where cardiologists know their data better than any other specialists out there, and expect their reps to as well. Unlike the other teams who worry more about where they should place their copay cards in the waiting rooms and what new and creative lunches they can bring in, the CV team has actually been clinically selling the crap out of Pradaxa and engaging physicians with DATA. And they have had to be on top of their game at all times all these years because improper usage, side effects, drug interactions of OACs can mean a trip to the ICU or even the morgue, not just a dry mouth or some rash in your crotch. Management knows this and they are going to keep their A-team in place. So run along to your PCP offices and keep yourself busy sample dropping and catering, and we will see where the chips fall when the time comes...
 




You are so right! I’m going to ask my CBD if I can leave my RBS/DBS position (not saying which I am) to sell Pradaxa. I know I can get my share up to 2.1% while Eliquis, and even Xarelto eats my lunch.
 




anonymous said:
You are so right! I’m going to ask my CBD if I can leave my RBS/DBS position (not saying which I am) to sell Pradaxa. I know I can get my share up to 2.1% while Eliquis, and even Xarelto eats my lunch.
Click to expand...
HSBS here you’re onto something- just like the CV; our teams actually have to perform better than competition by offering crucial clinical information.
Heard that top talent will be getting tapped on the shoulder for the new ILD expansion. You sound like the type we need in this new stable. We both sell and carry the weight over the primary care leaches in other divisions
 




anonymous said:
You're funny. The CV team is BY FAR the most clinically savvy selling group in B.I. They have been battling the competition for years now with probably 1/4 the resources and headcount that Eliquis and Xarelto have had, all within an arena where cardiologists know their data better than any other specialists out there, and expect their reps to as well. Unlike the other teams who worry more about where they should place their copay cards in the waiting rooms and what new and creative lunches they can bring in, the CV team has actually been clinically selling the crap out of Pradaxa and engaging physicians with DATA. And they have had to be on top of their game at all times all these years because improper usage, side effects, drug interactions of OACs can mean a trip to the ICU or even the morgue, not just a dry mouth or some rash in your crotch. Management knows this and they are going to keep their A-team in place. So run along to your PCP offices and keep yourself busy sample dropping and catering, and we will see where the chips fall when the time comes...
Click to expand...


Is this comedy hour???

BI is trying to hold at best Pradaxa business. This job is sample dropping and feeding cath labs on a good day.

I believe you were playing dear Mr. Fantasy in your mind while writing this post.
 




Please people seriously. Yea CV reps are clinically selling while the other teams are not. Just like the new ranking that came out. The rep at the top is now down down. Great one day mediocre the next.
 




I launched Pradaxa in the day and now I am in another division. You are correct that clinical is everything in Cardiology, and we all knew our stuff cold. It was the best experience I ever had in pharma. Now it has been a few years and all the Cardiologists know everything and there is really nothing new you can tell them. We got killed with bad drug, but the company really messed up by not having the reversal at or near launch. They didn't think it was necessary. If that had happened, no competition could have even entered the market. Great drug. The truth is there are great reps in all divisions and positions and there are horrible reps in all divisions. It is nice to have a little respect for each other because we are all on the same boat.
 








anonymous said:
HSBS here you’re onto something- just like the CV; our teams actually have to perform better than competition by offering crucial clinical information.
Heard that top talent will be getting tapped on the shoulder for the new ILD expansion. You sound like the type we need in this new stable. We both sell and carry the weight over the primary care leaches in other divisions
Click to expand...

HSBS? Sell?...Bwahhh haaah haahhh haaaahh!
 




anonymous said:
I launched Pradaxa in the day and now I am in another division. You are correct that clinical is everything in Cardiology, and we all knew our stuff cold. It was the best experience I ever had in pharma. Now it has been a few years and all the Cardiologists know everything and there is really nothing new you can tell them. We got killed with bad drug, but the company really messed up by not having the reversal at or near launch. They didn't think it was necessary. If that had happened, no competition could have even entered the market. Great drug. The truth is there are great reps in all divisions and positions and there are horrible reps in all divisions. It is nice to have a little respect for each other because we are all on the same boat.
Click to expand...

+1
 




























There's a # of vacancies at this point around the country that are not being filled in both resp. and diabetes. Something is absolutely coming. Who knows what, but something. You don't leave territories vacant for months on end unless SOME kind of change is coming. All rumors point to Q2. No one seems to know specifics. Lots of crap flying around, but none of it is confirmed. Seems we have no choice but to sit tight and wait to hear something. Company should do it soon though, people are talking, and they are not discussing good things.
 




anonymous said:
There's a # of vacancies at this point around the country that are not being filled in both resp. and diabetes. Something is absolutely coming. Who knows what, but something. You don't leave territories vacant for months on end unless SOME kind of change is coming. All rumors point to Q2. No one seems to know specifics. Lots of crap flying around, but none of it is confirmed. Seems we have no choice but to sit tight and wait to hear something. Company should do it soon though, people are talking, and they are not discussing good things.
Click to expand...
The territories are empty because BI pay is so horrible. In a major NE city they literally cannot fill 2 respiratory positions. Peeps interview,hear the base,figure out bonus thru grapevine and say NO THANKS!!
 




anonymous said:
The territories are empty because BI pay is so horrible. In a major NE city they literally cannot fill 2 respiratory positions. Peeps interview,hear the base,figure out bonus thru grapevine and say NO THANKS!!
Click to expand...


Sorry...the jobs are not even posted on the website and haven't been for 2 quarters. Only listings are HSBS and animal health.
 




Heard there is going to be a POA meeting the week of May 20th or around that time for respiratory...strong rumor. Probably regarding the Stiolto indication. So if that's the case.... There's also a rumor going around that there is going to be a strong push for ipf late second-quarter, new openings, and management isn't sure how many bi reps will be apply for that. So that could be the reason that they are holding off on hiring open positions right now because they don't know if Ashfield has to fill them or BI can to fill them. An Ashfield manager once told me they're supposed to have 25% of the sales force on their contract, per the contract. Who knows though. I wouldn't stress too much about it. Worry about what you can control and the rest will fall into place.
 




anonymous said:
Heard there is going to be a POA meeting the week of May 20th or around that time for respiratory...strong rumor. Probably regarding the Stiolto indication. So if that's the case.... There's also a rumor going around that there is going to be a strong push for ipf late second-quarter, new openings, and management isn't sure how many bi reps will be apply for that. So that could be the reason that they are holding off on hiring open positions right now because they don't know if Ashfield has to fill them or BI can to fill them. An Ashfield manager once told me they're supposed to have 25% of the sales force on their contract, per the contract. Who knows though. I wouldn't stress too much about it. Worry about what you can control and the rest will fall into place.
Click to expand...

So why aren't they filling diabetes and cardio positions? Only HSBS are being filled.
 




Top Bottom
Back
Quote